On the other hand, in-vivo CD27 engagement by CD70 on B-cells has shown to augment primary CD8+T-cell responses and tumor rejection even in poorly immunogenic tumor models, as CD27 stimulation can boost antigen-specific CD8+T-cell expansion and concomitantly improve per-cell cytotoxic functionality [165]. The gene discussed is CD27; the disease is neoplasm.